Redox‐Active Metal Complexes for Anticancer Therapy

Zhang, Pingyu; Sadler, Peter J.

doi:10.1002/ejic.201600908

Cited by 198 publications

(132 citation statements)

References 88 publications

(167 reference statements)

Supporting

Mentioning

125

Contrasting

Unclassified

Order By: Relevance

“…[4][5][6] Coordination compounds with metals other than platinum, particularly ruthenium(II)-based complexes, are emerging as promising antiproliferative and antimetastatic agents with potential uses. Since FDA approval in 1978, cisplatin, [7][8][9][10] has been used in medical cancer treatment, which is notable as it was the first transition metal complex found to have anticancer activity. It is also worth to stress that cisplatin is effective against cancers such as sarcomas, carcinomas (small cell lung and ovarian cancer), lymphomas, and germ cell tumours.…”

Section: Introductionmentioning

confidence: 99%

New Findings in Metal Complexes with Antiproliferative Activity Containing 1,3,5‐Triaza‐7‐phosphaadamantane (PTA) and Derivative Ligands

et al. 2019

View full text Add to dashboard Cite

This minireview summarizes some of the most significant findings published in the last years on metal complexes containing PTA and PTA derivatives ligands such as dmoPTA, with antiproliferative activity [PTA = 1,3,5-triaza-7-phospha- [a] 1529 Pablo Lorenzo-Luis completes his B.Sc. Degree at La Laguna-University-ULL and he received his Ph.D. from the same University (July 1998) under the supervision of Full Professor P. Gili. Soon after, he moved to ISSECC-CNR-Florence, Italy with Dr. S. Midollini where he worked in the Metal Phosphonate Chemistry. He spent two months (2001) in the same place (now ICCOM-CNR) with Dr. M. Peruzzini conducting basic research on Organometallic Chemistry and Catalysis. He is currently as Lecturer at that University (ULL-Inorganic Chemistry Section from 2004-) and co-author of more than a sixty scientific papers in peer-reviewed journals and he has been supervisor of several Ph.D. students on ruthenium complexes with "Doctor Europaeus Mention". Eur. J. Inorg. Chem. 2019, 1529-1538 www.eurjic.org

show abstract

Section: Introductionmentioning

confidence: 99%

New Findings in Metal Complexes with Antiproliferative Activity Containing 1,3,5‐Triaza‐7‐phosphaadamantane (PTA) and Derivative Ligands

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Metal complexes have been investigated in the development of new therapeutic strategies to treat solid tumors A few platinum(IV) and ruthenium(III) prodrugs have already reached clinical trials . The selectivity of these prodrugs depends on redox activation in the hypoxic regions of solid tumors.…”

Section: Introductionmentioning

confidence: 99%

“…Despite some advantages when compared to platinum(II) drugs, as the possibility of oral administration, so far none obtained worldwide approval for clinical use . Other metals have also been exploited, such as copper, iron and cobalt , . Cobalt is a promising alternative to platinum and ruthenium due to its abundance and therefore lower cost, reduced toxicity (it is an essential trace element) and two oxidation states accessible under biological conditions – an inert Co 3+ (low spin 3d 6 ) and a labile Co 2+ (high spin 3d 7 ) configuration , .…”

Section: Introductionmentioning

confidence: 99%

“…Cobalt is a promising alternative to platinum and ruthenium due to its abundance and therefore lower cost, reduced toxicity (it is an essential trace element) and two oxidation states accessible under biological conditions – an inert Co 3+ (low spin 3d 6 ) and a labile Co 2+ (high spin 3d 7 ) configuration , . Some of these features allow a wide range of potential applications not only in medicinal chemistry,, , but also in the development of molecular materials, and catalysts for water splitting and CO 2 reduction, among others. Differently from platinum and ruthenium, the metal is not responsible for the activity of cobalt prodrugs.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Investigation of Cobalt(III)‐Tetrachlorocatechol Complexes as Models for Catechol‐Based Anticancer Prodrugs

et al. 2019

View full text Add to dashboard Cite

Two novel cobalt(III) complexes, [Co(TPA)(TCC)]ClO4·H2O (1) and [Co(py2en)(TCC)]ClO4·2H2O (2), were synthesized and fully characterized by IR, UV/Vis and 1H NMR spectroscopy, ESI mass spectrometry, and X‐ray diffraction. Cyclic voltammetry experiments revealed an irreversible reduction of the Co3+ center for both complexes. The Co3+/Co2+ redox potential, –0.91 V for 1 and –1.15 V for 2 (vs. Fc/Fc+), was obtained by square wave voltammetry in DMSO. Reactions of 1 and 2 with ascorbic acid and sodium dithionite at pH 7.4 and 6.2 were carried out in argon and open‐air atmospheres, to simulate biological redox activation under hypoxia and normoxia. Neither the Co3+/Co2+ reduction nor the dissociation of TCC2– was observed. Thermodynamic parameters calculated for the Co3+/Co2+ reduction and substitution of the TCC2– ligand by water indicate an endothermic non‐spontaneous reaction.

show abstract

“…Fichtner et al 2012 reported that silver-carbene complexes were a potent cytotoxic and resistant-breaking anticancer agent, but unfortunately, their efficacy was at the expense of high toxic effect and low selectivity in in vivo setting [62]. However, the type of ligands that attached to the metal can contribute to its anticancer properties as they can be involved in target recognition and interfere in biochemical pathways [63]. e presence of phosphine ligands increases the lipophilicity and membrane permeability of metal-based complexes that make them active [64].…”

Section: Antiplasmodial Activitymentioning

confidence: 99%

New Silver Complexes with Mixed Thiazolidine and Phosphine Ligands as Highly Potent Antimalarial and Anticancer Agents

Sofyan

Nordin

Razak

et al. 2018

Journal of Chemistry

View full text Add to dashboard Cite

Five silver(I) complexes containing a mixed ligand system of phosphine and thiazolidine were successfully synthesized. e structural information of the complexes was assembled using various spectroscopic techniques such as CHN elemental analysis, Fourier transformed infrared (FTIR), 1 H, 13 C, and 31 P{ 1 H} NMR spectroscopy, and thermogravimetric analysis (TGA). A bidentate phosphine ligand acted as a chelating agent which bond to the silver in 1 : 2 molar ratios. Meanwhile, thiazolidine was attached to the silver in a 1 : 1 molar ratio. e antiplasmodial properties of all synthesized complexes were investigated on chloroquine-resistant P. falciparum parasite via HRP2 assays and cytotoxicity tests on Vero cells. Of all the synthesized complexes, complex 2 showed the highest SI value (more than 12.4) followed by complex 5 (6.6). e potent properties of compounds 2 and 5 were also noted in the in vitro antiproliferative assays involving MDA-MB-231 and MCF-7 breast cancer cell lines as well as HT-29 colon cancer cell line. Complex 2 was selective for MDA-MB-231 cells (GI 50 � 1.9 ± 0.3 µM), while complex 5 acted predominantly on breast carcinoma cells (GI 50 MDA-MB-231 � 4.7 ± 1.1 µM; MCF-7 � 2.9 ± 0.9 µM) instead of colon carcinoma (HT-29) cells (GI 50 � 15.1 ± 1.9 µM).

show abstract

Redox‐Active Metal Complexes for Anticancer Therapy

Cited by 198 publications

References 88 publications

New Findings in Metal Complexes with Antiproliferative Activity Containing 1,3,5‐Triaza‐7‐phosphaadamantane (PTA) and Derivative Ligands

New Findings in Metal Complexes with Antiproliferative Activity Containing 1,3,5‐Triaza‐7‐phosphaadamantane (PTA) and Derivative Ligands

Investigation of Cobalt(III)‐Tetrachlorocatechol Complexes as Models for Catechol‐Based Anticancer Prodrugs

New Silver Complexes with Mixed Thiazolidine and Phosphine Ligands as Highly Potent Antimalarial and Anticancer Agents

Contact Info

Product

Resources

About